| 名稱(chēng) | LMNA-NTRK1/BaF3 |
| 型號(hào) | CBP73202 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | LMNA-NTRK1/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- Cell Rep：發(fā)現(xiàn)治療乳腺癌轉(zhuǎn)移的重要新靶標(biāo)！
- 老靶點(diǎn)迭代突破創(chuàng)新：Her2靶點(diǎn)細(xì)胞模型
- EGFR 20外顯子突變類(lèi)型標(biāo)準(zhǔn)品
- sigma試劑的抗菌作用機(jī)制分析
- 【產(chǎn)品推介】TMB診斷標(biāo)準(zhǔn)品
- 一起認(rèn)識(shí)下腫瘤細(xì)胞的遷移性
- FLT3基因檢測(cè)標(biāo)準(zhǔn)品
- 【產(chǎn)品推介】NRAS診斷標(biāo)準(zhǔn)品
- 【產(chǎn)品推介】IL12細(xì)胞篩選模型
- PLoS ONE：科學(xué)家發(fā)現(xiàn)癌癥轉(zhuǎn)移的新線索
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73202LMNA-NTRK1/BaF3
- 詳細(xì)內(nèi)容
CBP73202 | |
| I. Introduction | |
Cell Line Name： | LMNA-NTRK1/BaF3 |
Host Cell: | BA/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) | |
| III. Representative Data | |
1. WB of LMNA-NTRK1/BaF3 expression | |
| |
2. Sanger of LMNA-NTRK1/BaF3 expression
Figure 2. Sanger Sequencing of LMNA-NTRK1/BaF3 | |
3. Anti-proliferation assay | |
| |
Figure 3. Anti-proliferation assay of two reference compounds on the LMNA-NTRK1/BaF3 Stable Cell Line | |
會(huì)員_a.png)